Skip to content
Biodatica
Start free

Seagen, a wholly owned subsidiary of Pfizer

Anchorage, Alaska

OncologyADCPhase IIIListed · PFE

This company trades under its own ticker, so it sits outside Biodatica’s pre-ticker window. The record stays here because its filings are real, but the feed leaves listed companies out unless you ask for them.

Compare Sign in to watch

What changed

Phase I trial registered: A Study of Sigvotatug Vedotin in Advanced Solid Tumors

1w agoTrial registeredJul 6, 2026Source filing (opens the source filing in a new tab)

Momentum

100no change

Momentum 100 out of 100, unchanged since the last recompute.

Accelerating: several high-weight events landed recently.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Phase III

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

  1. Trial

    PHASE2 registered

    May 20, 2024

    Breast Neoplasms, Gastroesophageal Junction Adenocarcinoma, HER2 Low Breast Neoplasms, HER2 Positive Breast Neoplasms, Stomach Neoplasms, Triple Negative Breast Neoplasms, Metastatic Breast Cancer, Metastatic Gastric Cancer, Advanced Breast Cancer, Advanced Gastric Cancer · ACTIVE_NOT_RECRUITING · sponsor: Seagen, a wholly owned subsidiary of Pfizer · A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors

    ClinicalTrials.gov · NCT06157892 (opens the source filing in a new tab)

  2. Trial

    PHASE1 registered

    Feb 29, 2024

    Lymphoma, T-Cell, Cutaneous, Hodgkin Disease, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Non-Hodgkin · TERMINATED · sponsor: Seagen, a wholly owned subsidiary of Pfizer · A Safety Study of PF-08046045/SGN-35T in Adults With Advanced Cancers

    ClinicalTrials.gov · NCT06120504 (opens the source filing in a new tab)

  3. Trial

    PHASE1 registered

    Nov 20, 2023

    Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Stomach Neoplasms, Pancreatic Ductal Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Small Cell Lung Carcinoma · RECRUITING · sponsor: Seagen, a wholly owned subsidiary of Pfizer · A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors

    ClinicalTrials.gov · NCT06131840 (opens the source filing in a new tab)

  4. Trial

    PHASE1 registered

    Jan 3, 2023

    Cutaneous Melanoma, Non-small Cell Lung Cancer, Colorectal Neoplasms, Pancreatic Neoplasms, Mesothelioma · TERMINATED · sponsor: Seagen, a wholly owned subsidiary of Pfizer · A Study of PF-08046049/SGN-BB228 in Advanced Melanoma and Other Solid Tumors

    ClinicalTrials.gov · NCT05571839 (opens the source filing in a new tab)

  5. Trial

    PHASE1 registered

    Oct 25, 2022

    Carcinoma, Non-Small-Cell Lung, Squamous Cell Carcinoma of the Head and Neck, Esophageal Squamous Cell Carcinoma, Triple Negative Breast Neoplasms, Gastric Cancer, Endometrial Cancer, Pancreatic Adenocarcinoma, Hepatocellular Carcinoma · RECRUITING · sponsor: Seagen, a wholly owned subsidiary of Pfizer · A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors

    ClinicalTrials.gov · NCT05208762 (opens the source filing in a new tab)

  6. Trial

    PHASE2 registered

    May 3, 2022

    Urothelial Carcinoma · RECRUITING · sponsor: Seagen, a wholly owned subsidiary of Pfizer · A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2

    ClinicalTrials.gov · NCT04879329 (opens the source filing in a new tab)

  7. Trial

    PHASE1 registered

    Jun 8, 2020

    Carcinoma, Non-Small Cell Lung, Squamous Cell Carcinoma of Head and Neck, HER2 Negative Breast Neoplasms, Esophageal Squamous Cell Carcinoma, Esophageal Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Ovarian Neoplasms, Cutaneous Squamous Cell Cancer, Exocrine Pancreatic Adenocarcinoma, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Stomach Neoplasms · RECRUITING · sponsor: Seagen, a wholly owned subsidiary of Pfizer · A Study of Sigvotatug Vedotin in Advanced Solid Tumors

    ClinicalTrials.gov · NCT04389632 (opens the source filing in a new tab)

  8. Trial

    PHASE3 registered

    Oct 2, 2019

    HER2-positive Breast Cancer · ACTIVE_NOT_RECRUITING · sponsor: Seagen, a wholly owned subsidiary of Pfizer · A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer

    ClinicalTrials.gov · NCT03975647 (opens the source filing in a new tab)

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources